Brand and Strategy

What is out business strategy?

We plan to grow the business through the manufacture of organic products and development of the MOCA brand over the next one to three years.

During this time-frame, the Company will operate on a staged approach to leverage its licences and bring a variety of medical cannabis products into our secure medical facility in New South Wales, including CBD and THC capsules, CBD oils and tinctures, sublingual and concentrates. Our import licence enable us to wholesale our products to pharmacies, hospitals and licenced medical professionals. Our export licence enables the Company to sell products to licenced buyers around the world.

The Company will pursue its licence applications with New Zealand for importation and to establish a cultivation facility firstly for research and secondly for cultivation of marijuana for commercial sale.

We expect to generate revenue in 2019 as we have supply agreements with licenced cannabis cultivators in the United States and in Canada that enable us to import products into Australia immediately. According to Fortune Magazine Fortune, the U.S. cannabis industry could grow to $20 billion by 2022.